Paradigm Biopharmaceuticals
Follow
Get notifications in MyBN when activity occurs.
Industry Lists
Public Companies - non WAParadigm Biopharmaceuticals Limited (PAR) is an Australian biopharmaceutical company focused on repurposing the drug 'pentosan polysulphate sodium' (PPS) for the treatment of bone marrow edema.
Paradigm is targeting addressable markets with the aim to use the shortened development pathway utilising repurposed drugs.
Contact Details
Level 15, 500 Collins Street, MELBOURNE VIC 3000
03 9629 5566
Lists and Charts
Share price
Closing price for the last 90 trading days
Powered by Morningstar ®
Total Shareholder Return as at 31/10/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 1692nd | Paradigm Biopharmaceuticals | -65% | -41% |
1740 WA (and selected non WA) listed companies ranked by
1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| th |  | Paradigm Biopharmaceuticals | $6.1m |
1334 listed non wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Share Transactions
Total value as at the date of the transaction
Powered by Morningstar ®
Company Activity
| NEW ROLE: Matthew Fry, Non-Executive Director | 07 Aug 2024 |
| ECM DEAL: New deal has been added | 12 Feb 2024 |
| NEW ROLE: Helen Fisher, Non-Executive Director | 13 Apr 2022 |
| NEW ROLE: Amos Meltzer, Non-Executive Director | 22 Dec 2020 |
| NEW ROLE: Christopher Fullerton, Non-Executive Director | 03 Nov 2020 |
| NEW ROLE: Paul Rennie, Executive Director, Managing Director, Executive Chairman | 03 Nov 2020 |
| NEW ROLE: John Gaffney, Non-Executive Director | 03 Nov 2020 |
| NEW ROLE: Donna Skerrett, Executive Director | 03 Nov 2020 |
| NEW ROLE: Kevin G Hollingsworth, Company Secretary | 03 Nov 2020 |
